The current study was conducted to better characterize the association between overall survival (OS) from metastatic thyroid cancer and the rate of structural disease progression. METHODS: In this retrospective study, the average tumor volume doubling time (midDT) of 2 dominant lung metastases was used to group patients into 6 clinically relevant cohorts. OS was calculated from the time of metastasis diagnosis and from the time the pulmonary lesions crossed over the 1-cm diameter threshold. RESULTS: The tumor growth rate was remarkably constant in lung metastases from thyroid cancer over a median follow-up of 8.5 years (median correlation coefficient, 0.92; coefficient of determination, 0.85). Patients with a midDT 1 year were found to have worse OS compared with those with a higher midDT (log-rank P 5.01). The 5-year OS rate from the 1-cm diameter time point was 20% for patients with a midDT 1 year (15 patients), 50% for patients with a midDT of 1 to 2 years (19 patients), 53% for patients with a midDT of 2 to 3 years (9 patients), 80% for patients with a midDT of 3 to 4 years (6 patients), and 80% for patients with a midDT of 4 years or who were negative (12 patients). Within the group of patients with a midDT 1 year, the 2-year OS rate from the 1-cm diameter point was 88% in the patients treated with multikinase inhibitors (8 patients) versus 43% in the nontreated group (7 patients) (P 5.13). CONCLUSIONS: The midDT of lung metastases appears to be a good prognostic indicator of OS in patients with metastatic thyroid cancer. Unlike the thyroglobulin DT, the midDT alone can be used to predict eligibility for multikinase inhibitor therapy. Cancer 2017;123:2955-64. V C 2017 American Cancer Society.
INTRODUCTION
The development of distant metastases in follicular cell-derived thyroid carcinoma is associated with poor clinical outcomes, particularly in older patients. Reported 10-year overall survival (OS) rates of approximately 50% are noted among patients who present with distant metastases at presentation whereas the median progression-free survival is only 3.7 years after the identification of distant metastases.
1,2 Better outcomes have been described in young patients with small-volume radioactive iodine (RAI)-avid pulmonary metastases, 3 whereas a variety of clinical factors including aggressive tumor histology, marked [ 18 F]fludeoxyglucose (FDG) avidity, poor RAI avidity, older age, larger volume metastases, and metastatic foci outside the lungs have been associated with much poorer clinical outcomes. [2] [3] [4] [5] [6] Although these various clinicopathological risk factors provide some insight into the likely course of disease progression, they cannot accurately predict the rate of structural disease progression or progression-free survival within an individual patient. Previous studies have demonstrated that initial risk stratification estimates can be significantly improved when data accumulated during follow-up are used to modify risk estimates over time. 7, 8 For example, Miyauchi et al demonstrated that the doubling time (DT) of serum thyroglobulin values (TgDT) obtained during follow-up was a powerful predictor of locoregional disease recurrence, distant metastasis, and disease-specific survival. 9 Although serum Tg values reflect total body disease burden, it is the size of the metastatic lesions and the rate of structural disease progression that are used to define if and when clinicians should consider the initiation of systemic therapies. We recognized that patient survival is the product of the tumor burden and tumor growth rate. In that equation, we believe that the tumor growth rate is a stronger indicator of survival than the tumor burden itself. Thus, larger tumors that are stable are unlikely to cause a patient's death, whereas smaller tumors with a rapid growth curve are more likely to lead to a bad outcome. Therefore, it is important to define the tumor growth rate for any individual patient to more precisely predict clinical outcomes so that systemic therapy can be offered to the appropriate patient at the appropriate time. From a clinical standpoint, it would be helpful to know the anticipated OS from both 1) the time of discovery of the distant metastases and 2) the time that the pulmonary nodule crossed the 1-cm diameter boundary commonly used as the minimal threshold required to initiate systemic therapy.
Measuring tumor growth rate traditionally has been performed using either Response Evaluation Criteria In Solid Tumors (RECIST) in clinical trials or using changes in tumor diameter over a specific period of time in clinical practice. Alternatively, growth rate can be defined based on the time needed for a tumor to double over time, herein referred to as doubling time (DT). DT assumes that tumor growth is constant overtime. It can be measured based on tumor diameters or volume. RECIST have not been validated in clinical practice. Because the growth of metastatic lesions is associated with an increase in tumor volume rather than a unidimensional increase in size, and because tumor structural progression usually demonstrates a pattern of exponential growth that remains constant over time until large burdens of disease are achieved, we chose to define the tumor growth rate as tumor volume DT, which can be presented visually as straight lines on a semi-log graph. [10] [11] [12] [13] Therefore, the primary objective of the current study was to determine the rate of structural disease progression (as measured by tumor volume DT) in patients with lung metastasis from follicular cell-derived thyroid cancer. We hypothesized that the tumor volume DT (TVDT) of the metastatic tumor foci would remain constant over time and be a significant predictor of OS for individual patients.
MATERIALS AND METHODS

Patients
After obtaining Institutional Review Board (IRB) approval, we retrospectively reviewed the charts of 199 patients with follicular cell-derived thyroid cancer presenting with pulmonary metastases identified either at the time of diagnosis or during follow-up. These patients were followed at Memorial Sloan Kettering Cancer Center between 1992 and 2016. Their clinical characteristics previously were described in a prior study. 2 All patients were treated with total thyroidectomy and RAI ablation at the time of their thyroid cancer diagnosis. Patients received repeat RAI therapies and/or repeat surgery and/or external beam radiotherapy to the neck and/or bone metastasis and/or multikinase inhibitor (MKI) therapies during the course of follow-up and then at the discretion of their treating physician.
To accurately measure lung volume DTs, we included patients with 1 measurable lung lesions on at least 4 consecutive computed tomography (CT) scans of the chest. For patients who initiated MKI therapy, DTs were calculated before the initiation of MKI therapy.
We excluded patients with the following: 1) anaplastic or medullary thyroid cancer; 2) inadequate follow-up; 3) nonmeasurable disease (nodules measuring < 5 mm and stable or decreasing in size with time, nodules that were not clearly demarcated at the time of diagnosis or with follow-up, or nodules obscured by effusions); 4) age < 18 years at the time of diagnosis of metastatic thyroid cancer; 5) concomitant second primary cancer; or 6) chronic thyroid-stimulating hormone (TSH) elevation. Of 199 potential patients, 88 ultimately were included in the current study.
Evaluation of Lung Nodules
We included any measurable lung lesion, even those measuring <1 cm. When > 1 nodule was present (85 of 88 patients), we measured the 2 largest measurable lung lesions on serial CT.
Standard-dose CT images were acquired using spiral CT scanners. Over the years, the collimation used for each CT varied as the technology field advanced. To avoid variability in the measurements over the years, we selected a CT slice thickness of 5 mm for determining nodule sizes. All the nodules were measured by 1 physician (M.M.S.). Measurements were made using the same picture archiving and communication system (PACS) workstation. Longitudinal and transverse measurements were obtained by manually positioning electronic calipers on the CT image that demonstrated the largest detectable size of the selected nodule. Assuming that each metastatic nodule is ellipsoid in shape, we then calculated the tumor volume (in mL) for each nodule at each given time point using the following formula: p/6 longest diameter 3 smallest diameter 3 smallest diameter.
Laboratory Studies
Suppressed Tg levels were collected if obtained within 3 months of the nodules' measurements. Tg levels were not recorded if: 1) they were measured outside the 3-month window; 2) interfering anti-Tg levels were concomitantly measured; or 3) the associated TSH level was >5 mIU/L.
Recorded Tg levels were standardized to the International Standard CRM-457 reference preparation.
DT Measurements
Using the same concept previously used by Miyauchi et al to define TgDT, 9 and assuming that changes in tumor volume are exponential (as shown below), we computed a regression line, log y 5 log a 1 bx, using a nonlinear square regression with "x" defined as time (in years) after the initial CT chest scan and "y" defined as tumor volume. TVDT was calculated as (log 2)/b. We then calculated the average TVDT for each given patient (referred to herein as midDT) using the average of the calculated TVDTs of the 2 selected nodules.
We then calculated the TgDT for each patient with metastatic thyroid cancer using at least 3 consecutive Tg levels obtained within a 3-month window of the nodules' measurements. We then correlated the midDT and TgDT.
Statistical Analysis
Continuous data are presented as means and standard deviations or as median and ranges, as appropriate for each variable.
The first objective of the current study was to prove that tumor growth is exponential and constant over time. For this purpose, we analyzed the measured tumor volumes for each given nodule over time. A total of 146 structurally progressive nodules were included in this analysis. We calculated the correlation coefficient (r) and the coefficient of determination (r 2 ) for each given nodule.
The second objective was to determine whether the TVDT of the lung metastases could predict OS from metastatic differentiated thyroid cancer. Based on previously defined Tg and calcitonin DT prognostic breakpoints, we grouped patients into 6 clinically relevant groups based on their midDT: those with a midDT 1 years, those with a midDT of 1 to 2 years, those with a midDT of 2 to 3 years, those with a midDT of 3 to 4 years, those with a midDT of 4 years, and those with a negative midDT. 9, 14, 15 For this analysis, we grouped those patients with a midDT >4 years and those with a negative midDT together. Using Kaplan Meir survival analysis and log-rank testing, we calculated OS both from: 1) the diagnosis of the lung metastases and 2) from the time the largest nodule was 1 cm to estimate survival from the earliest time point that patients were likely to be considered for entry in a clinical trial.
We then grouped patients according to their TgDT: those with a TgDT 1 year, those with a TgDT of 1 to 2 years, those with a TgDT of 2 to 3 years, those with a TgDT of 3 to 4 years, and those with a TgDT of 4 years or negative. We repeated the OS analysis from the time the lung metastases diagnosis was established, and then from the 1-cm measurement time point.
Few patients with RAI-refractory (RAIR), structurally progressive, metastatic thyroid cancer were treated with MKI therapy alone or in combination with RAI. We were interested in determining whether patients with shorter structural DTs benefited from MKI therapy, when offered, irrespective of the drug (s) used and the estimated response to that therapy. For each midDT group, we examined the effect of MKI therapy effect on their OS using Kaplan-Meir survival curves and log-rank analyses.
Because patients with a midDT 1 year who were treated with MKI therapy appeared to have a survival benefit compared with those who were not treated, we then compared the clinical characteristics of patients treated with MKI with those of nontreated patients using the Pearson chi-square test and analysis of variance. We then selected 3 patients with a midDT 1 year and who were treated with MKI therapy and compared the tumor volume regression lines before and after MKI therapy.
All analyses were performed using SPSS statistical software (version 24; IBM Corporation, Armonk, NY). A P value .05 was considered to be statistically significant.
RESULTS
Patient Characteristics
The clinicopathological characteristics of the 88 patients are summarized in Table 1 .The patients had a median age of 54 years at the time of their diagnosis of distant metastases, with papillary (43%) or poorly differentiated (38%) histologies and predominantly subcentimeter pulmonary metastases (72%). The majority of patients had only lung metastases, with only 22% found to have additional metastatic lesions outside of the lung at the time of the diagnosis of lung metastases. The median size of the primary tumor was 3.4 cm (range, 0.7-16 cm).
The patients were followed for a median of 8.5 years (range, 0.7-29.4 years). The majority of patients (85%) had developed disease progression by the end of the follow-up period and greater than one-half of the patients had died (56%). Of the 49 patients who died, the primary cause of death was thyroid cancer (84%) followed by myelodysplastic syndrome in 6% of the cases. The cause of death was not known in 5 patients. 
Distribution of TVDT of Lung Metastases
A total of 88 patients had lung lesions attributed to thyroid cancer metastases. All but 3 patients had at least 2 measurable lung lesions. In keeping with RECIST, we elected to measure 2 nodules in 1 organ. 16 Over time, some of the lesions grew, others remained stable, and others decreased in size. Figure 1 depicts the regression lines of tumor volume changes with time of the 2 selected nodules (largest nodule is nodule 1 in panel A and the second largest nodule is nodule 2 in panel B) in 3 representative patients. Of the 146 progressive metastatic lung lesions, the tumor growth rate was remarkably constant over time, with a median follow-up of 8.5 years (median r, 0.92; r 2 5 0.85). For the cohort of 88 patients, the median size of the largest nodule was 1 cm and increased to 1.6 cm with a median DT of 1.3 years. The median size of the second largest nodule was 0.76 cm, and grew to approximately 1.2 cm with an equivalent median DT of 1.4 years ( Table  2 ). The median average TVDT of nodule 1 and nodule 2 (midDT) was equivalent to the median TVDT of either nodule (1.5 years vs 1.3 years for nodule 1 and 1.4 years for nodule 2).
The DT of nodule 1 correlated moderately well with that of nodule 2 (Pearson r, 0.48; r 2 5 0.23 [P<.001]). Assuming that the tumor growth of 2 dominant lesions is more representative of the overall clinical course than the DT of each separate nodule individually, we used the midDT as our primary outcome measure.
In general, the midDT ranged between -202.0 and 481.3 years. Table 3 summarizes the distribution of patients based on biochemical and structural DT (midDT). Based on the midDT, approximately 79% of patients had progressive disease in the lung from the time of the initial diagnosis of distant metastases, with 16 patients found to have rapidly progressive disease (midDT of 1 year), 38 patients found to have slowly progressive disease (midDT of 1-4 years), and 16 patients found to have very slowly progressive disease in the lungs (midDT of 4 years). A negative midDT was recorded in 18 patients, ranging between -0.93 and -202.0 years (median negative midDT, -11.5 years), reflecting the stability or slight decline in the average tumor volume overtime after RAI therapy and TSH suppression therapy. At the time of the diagnosis of distant metastases, approximately one-half of the patients were classified as having RAI-avid lung metastases. The median midDTs were similar in the RAI-avid patients (46 patients; median midDT of 1.43 years) and RAIR patients (42 patients; median midDT of 1.50 years). Similarly, the median midDTs were similar between patients with disease that was avid for FDG-positron emission tomography (PET) (30 patients; median midDT of 1.41 years) and patients with FDG-PET-negative metastatic thyroid cancer (36 patients; median midDT of 1.65 years). Thus, we anticipate that the effect of intervening therapies on the midDT was minimal.
Using chi-square analysis, we did not demonstrate a statistically significant correlation between the midDT and patient age, sex, RAI avidity, FDG-PET positivity, or the presence of other distant metastatic sites. However, not surprisingly, patients with Hurthle cell or poorly differentiated thyroid cancer were more likely to have a shorter midDT compared with those with more differentiated tumors (P<.001).
Thyroglobulin DT
A total of 81 patients had serial Tg levels that fit our inclusion criteria. The median Tg level at the time of the first CT scan was 38 ng/mL (range, 0.3-44,500.0 ng/mL) and rose to a median of 156 ng/mL (range, 0.2-158,000.0 ng/ mL) ( Table 2 ). The median TgDT was 0.8 years.
The TgDT and midDT demonstrated a moderate correlation (Pearson r, 0.50; r 2 , 0.25 [P<.001]). A similar percentage of patients had progressive disease (DT positive) based on the TgDT as by the midDT (81% vs 79%) ( Table 3 ). Table 4 shows a similar distribution of TgDT and midDT with the shortest midDT (2 years), longest midDT (4 years), and negative DTs, with more variability in the distribution of TgDT and midDT noted when the DT measured between 2 and 4 years. Figure 2 depicts the Kaplan-Meier curves for OS in the cohort of patients based on the midDT and TgDT groups. Survival was measured from the time of diagnosis of distant metastases ( Fig. 2A and 2C ) and from the time the lung lesion reached 1 cm (Fig. 2B and 2D ). The median OS from the time of diagnosis of lung metastases was 9.8 years (95% confidence interval, 8.8-10.9 years). The median OS from the 1-cm time point was 5.2 years (95% confidence interval, 3.2-7.2 years).
Association Between OS and Rate of Disease Progression
Patients with a DT of <1 year fared worse than patients with a higher DT. This was true for both the TgDT and midDT from either the time of diagnosis of lung metastases or from the time the largest lung lesion measured 1 cm. The 5-year OS rate from the 1-cm time point was 20% for a midDT 1 year (15 patients), 50% for a midDT of 1 to 2 years (19 patients), 53% for a midDT of 2 to 3 years (9 patients), 80% for a midDT of 3 to 4 years (6 patients), 86% for a midDT of 4 years (8 patients), and 52% for those with a negative midDT (4 patients) ( Table 5 ).
Initial Observation of the Effect of MKI Therapy on OS and TVDT
A total of 27 of the studied patients were treated with MKI therapy during the course of their follow-up: 9 patients (33%) with a midDT 1 year, 8 patients (30%) with a midDT of 1 to 2 years, 4 patients (15%) with a midDT of 2 to 3 years, 1 patient (3%) with a midDT of 3 to 4 years, and 5 patients with a midDT 4 years or negative midDT (19%).
Of the 15 patients with a midDT 1 year, 8 were treated with MKI and could be followed from the time the largest lung nodule measured 1 cm. The median follow-up from the 1-cm time point was 2.4 years. The 2-year OS rate from the 1-cm time point was 88% in the patients treated with MKIs (8 patients) versus 43% in the patients who were not treated with MKIs (7 patients) (P 5 .13). There was no difference in the clinical characteristics of the patients who received MKI and those who did not (data not shown). A survival benefit for MKI was not demonstrated when a similar analysis was performed 
Abbreviations: DT, doubling time; midDT, average tumor volume doubling time; TgDT, thyroglobulin doubling time; y, years.
on patients with a midDT between 1 to 2 years, 2 to 3 years (data not shown), or 3 to 4 years (data not shown). Figure 3 depicts the pattern of tumor volume regression lines before and after MKI therapy in 3 patients with a midDT <1 year. Although all 3 patients demonstrated an acute decrease in tumor volume within a few weeks after MKI therapy, the DT or tumor growth rate of the index lesion while the patient was receiving chronic MKI therapy varied widely.
DISCUSSION
In the current study, we introduced midDT as a novel clinical marker used to define structural disease progression in patients with lung metastases from differentiated thyroid cancer. Given that tumors do not grow in a linear fashion, we estimated that change in tumor volume is a more accurate measurement of growth than change in the longest diameter of a given lesion. Tumor growth rate in the lungs is remarkably constant, allowing for reliable measurement of TVDT. Lung midDT is measured easily through serial, retrospective review of 4 consecutive chest CT scans obtained at any time during the follow-up of the patient. Using the initial DT concept of Miyauchi et al, 9 the Kuma clinic in Tokyo published a DT and progression calculator that helps physicians to estimate tumor growth based on biochemical marker changes and tumor volume changes (http://www.kuma-h.or.jp/english). Using the Kuma calculator, treating physicians in the community can easily and rapidly estimate the TgDT and midDT during clinic visits. Furthermore, the selected clinically relevant midDT groups have been shown to predict overall prognosis from thyroid cancer, thereby allowing physicians to appropriately risk-stratify patients in the clinic, thus predicting early on which patients are more likely to progress rapidly as opposed to the slow progressors. Treatment approaches and the frequency of the follow-up imaging and visits can be tailored accordingly.
Patients with metastatic thyroid cancer with a midDT 1 year have a worse prognosis that those with a higher midDT. Prior studies have demonstrated that the 1-year time point in DT equally predicts worse prognosis when using TgDT, and calcitonin and carcinoembryonic antigen DT in patients with medullary thyroid cancer. The results of the current study further validate the prognostic value of TgDT in patients with differentiated thyroid cancer. It is not surprising that, in the current study, TgDT did not correlate with the midDT. TgDT is a biochemical estimate of the total body tumor volume growth rate, whereas midDT estimated only tumor growth occurring within a specific organ. Although both TgDT and midDT are prognostic indicators for patients with metastatic thyroid cancer, biochemical disease progression alone is not an eligibility criterion for consideration for MKI therapy. Conversely, structural progression alone, measured as the midDT, can be used to select patients for MKI therapy. In the future, we anticipate that calculations of both lung midDT and TgDT can be used jointly to risk-stratify patients and make treatment decisions. Thus, although the decision to treat is relatively straightforward for patients with both TgDT and a lung midDT 1 year, strong considerations would be made to treat those individuals with a TgDT 1 year but with a longer midDT (ie, a midDT of 1-4 years).
There continues to be a lack of uniform consensus regarding the ideal time for the initiation of MKI therapy in patients with RAIR, metastatic, follicular cell-derived thyroid cancer. Although the presence of clinically measurable disease (ie, lesions measuring > 1-1.5 cm) is a minimum requirement for consideration of MKI therapy, the inclusion criteria for the prospective randomized registration trials for sorafenib and lenvatinib required at least a 20% increase in the sum of the longest diameters of the target lesions defined by RECIST over either a 13-month (lenvatinib) or 14-month (sorafenib) period. 17, 18 Assuming that tumor growth rate is constant overtime (as shown in the current study) and using unidimensional tumor growth patterns, this would approximately equate to a DT of 4 years. Conversely, based primarily on expert opinion, the 2015 American Thyroid Association guidelines for thyroid cancer management suggest that a 20% increase in the longest tumor diameter over a 6-month period should prompt consideration of MKI therapies. This correlates with a DT of approximately 2 years ( 40% growth over 1 year). 19 The National Comprehensive Cancer Network guidelines cautiously avoided defining a specific tumor growth rate or tumor size that would prompt the use of MKI therapy in patients with RAIR differentiated thyroid cancer or medullary thyroid cancer. 20 Thus, based on the above summarized criterion, patients with structurally progressive, clinically measurable lung lesions with a tumor diameter DT of 2 to 4 years would be considered for the initiation of MKI therapy, whereas those individuals with lesions with a tumor diameter DT >4 years would be observed. However, RECIST are not validated in the clinical setting outside of prospective clinical trials. In addition, these unidimensional growth rate patterns can underestimate tumor volume growth over time and to the best of our knowledge have not been correlated with OS from metastatic RAIR thyroid cancer. Furthermore, using the above eligibility criteria for study entry, neither lenvatinib nor sorafenib therapy in patients with RAIR metastatic thyroid cancer demonstrated a significant survival benefit when compared with placebo. Thus, these eligibility criteria alone are not enough to select patients who are likely to benefit from MKI therapy. It is important to note that, due to its retrospective design, the current study was not intended to provide a head-to-head comparison of one tumor growth rate definition over another.
The results of the current study not only validate the use of midDT as a prognostic indicator in patients with lung metastasis from differentiated thyroid cancer in the clinical practice setting, but our preliminary observations also hint at a survival benefit with MKI therapy in patients with a midDT 1 year. It is not surprising that the survival benefit in the patients treated with MKIs was not statistically significant given the small number of patients studied. When examining the regression lines before and after MKI therapy, it became evident that despite an initial significant drop in tumor size and volume (which may be considered as a response to therapy) the long-term TVDT after the lung lesion reached its nadir size was quite varied among the 3 patients studied. We postulate that the response to MKI therapy and long-term survival after its use are more a function of that long-term TVDT rather than the acute tumor shrinkage observed within the first weeks after the initiation of MKI therapy. To further examine the efficacy of MKI therapies in patients with thyroid cancer, we currently are in the process of conducting further studies examining the effect of MKI therapy on OS and the change in TVDT before and after specific MKI therapy in a larger cohort of patients. In the interim, the data from the current study support the use of midDT as a useful clinical marker with which to properly select patients who are likely to benefit from the initiation of MKI therapy. We postulate that the early selection and treatment of patients with RAIR metastatic thyroid cancer and a midDT 1 year would improve treatment response and OS with MKI therapy. In addition, proper patient selection would prevent patients with slow TVDT being exposed to toxic, potentially fatal and costly drugs that are unlikely to benefit them clinically.
The current study is a retrospective review of patient charts and therefore is subject to all associated biases, including selection bias. We assumed that the measured lung lesions were thyroid cancer metastasis based on the overall clinical picture. We were careful not to measure ground glass nodules. In a few patients, a wedge biopsy was performed to confirm lung metastasis from thyroid cancer. In others, prior RAI avidity confirmed lung metastasis from thyroid cancer. Nonetheless, it is possible that some stable or slowly progressive lung lesions may represent inflammatory changes and/or indolent bronchoalveolar cancer.
Many of the patients in the current study had disease considered to be RAI avid at the time of the diagnosis of lung metastasis on the basis of uptake on the first posttherapy scan. These patients were treated with repeat RAI therapies. We previously demonstrated that >50% of the patients eventually present with disease progression despite repeat RAI therapies and ultimately are considered to have RAIR disease. 6 In the current study, approximately 85% of patients had progressive disease at the end of the follow-up period. However, we recognize that in the tumors that are truly responsive to RAI, repeat RAI therapy may have influenced the TVDTs. This is especially true for patients with RAI-responsive tumors who are predicted to have negative midDT or a midDT of >4 years after these therapies. To eliminate transient RAI response in partial RAI responders, we purposely elected not to measure lung volumes within 18 months after RAI therapy.
The average TVDT (midDT) of lung metastasis is an accessible, easily calculated, and reliable prognostic indicator of OS in patients with metastatic differentiated thyroid cancer and can be used to identify patients with RAIR metastatic thyroid cancer who are likely to benefit from MKI therapy.
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